Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in co-promotion and co-marketing dealmaking

2.1. Introduction
2.2. Difference between co-promotion and co-marketing deals
2.3. Trends in co-promotion deals since 2000
2.4. Trends in co-marketing deals since 2000
2.4.1. When co-marketing can be useful
2.4.2. When co-marketing is the only option
2.5. Pure deals and multi-component deals
2.5.1. Attributes of pure co-promotion deals
2.5.2. Attributes of co-promotion in multi-component deals
2.6. Reasons for including co-promotion options in a deal
2.7. Uptake of co-promotion rights
2.8. Co-promotion rights as bargaining chips
2.9. Aligning partners to make the co-promote work
2.10 The future of co-promotion as part of multicomponent deals
Chapter 3 - Overview of co-promotion deal structure

3.1. Introduction
3.2. Pure versus multi-component co-promotion deals
3.3. Pure co-promotion agreement structure
3.3.1. Example co-promotion agreements
3.3.1.a. Case study 1: GlaxoSmithKline - Allergan - September 2005
3.3.1.b. Case study 2: Cardinal Health - Bone Care - July 2004
3.4. Co-promotion rights as part of a wider alliance agreement
3.4.1. Example co-promotion option clauses
3.4.1.a. Case study 3: Novartis - Anadys - June 2005
3.4.1.b. Case study 4: AstraZeneca - Dynavax - September 2006
3.4.2. Example co-promotion right clauses
3.4.2.a. Case study 5: Gilead - Achillion - November 2004
3.4.2.b. Case study 6: Merck - Ariad - July 2007
3.5. Embedded co-promotion rights enabling third party engagement
3.5.1. Example co-promotion clauses enabling third party engagement
3.5.1.a. Case study 7: UCB - ImClone - August 2005
Chapter 4 - Overview of co-marketing deal structure

4.1. Introduction
4.2. Co-marketing agreement structure
4.2.1. Example co-marketing agreements
4.2.1.a. Case study 8: Helix Biomedix - Body Blue Inc - November 2004
4.3. Co-marketing rights as part of a wider alliance agreement
4.3.1. Example co-marketing right clauses
4.3.1.a. Case study 9: Alcon - NovaCal - September 2006
Chapter 5 - Leading co-promotion deals

5.1. Introduction
5.2. Top co-promotion deals by value
5.3. Top pure co-promotion deals
5.4. Top co-promotion deals signed by bigpharma
5.5. Most active co-promotion dealmakers
5.6. Bigpharma co-promotion deal activity
Chapter 6 - Leading co-marketing deals

6.1. Introduction
6.2. Top co-marketing deals by value
6.3. Top pure co-marketing deals
6.4. Top co-marketing deals signed by bigpharma
6.5. Most active co-marketing dealmakers
6.6. Bigpharma co-marketing deal activity
Chapter 7 - Bigpharma co-promotion and co-marketing agreements
Abbott
Actavis
Allergan
Amgen
Astellas
AstraZeneca
Barr
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Chugai
CSL
Daiichi Sankyo
Eisai
Eli Lilly
Forest Laboratories
Genentech
Genzyme
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
King
Lundbeck
Menarini
Merck & Co
Merck – Serono
Mitsubishi
Mundipharma
Novartis
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Procter & Gamble
Ratiopharm
Roche
Sanofi-Aventis
Schering Plough
Servier
Shire
Solvay
Stada
Takeda
Teva
UCB
Watson
Wyeth

7.1. Introduction
7.2. How to use co-promotion and co-marketing agreements
7.3. Company co-promotion and co-marketing agreement listings

Chapter 8 - Co-promotion agreement directory 2003-7

8.1. Introduction
8.2. Company A-Z
8.3. By therapy area
Accident/Hospital/Trauma
Blood/Lymphatic System
Cardiovascular
Central nervous System
Dermatology
Gastrointestinal
Genitourinary
Autoimmune/Inflammatory
Infection
Metabolism
Musculoskeletal
Oncology
Respiratory
Sensory Organ / Oral Health
Drug Delivery
8.4. By stage of development at signing
Discovery
Preclinical
Phase I
Phase II
Phase III
Registration
Market
Chapter 9 - Co-marketing agreement directory 2003-7

9.1. Introduction
9.2. Company A-Z
9.3. By therapy area
Accident/Hospital/Trauma
Blood/Lymphatic System
Cardiovascular
Central nervous System
Dermatology
Gastrointestinal
Genitourinary
Genetic
Autoimmune/Inflammatory
Infection
Metabolism
Musculoskeletal
Oncology
Respiratory
Sensory Organ / Oral Health
9.4. By stage of development at signing
Discovery
Preclinical
Phase I
Phase II
Phase III
Registration
Market
Appendices

Appendix 1 - Co-promotion/co-marketing references
Appendix 2 - Resources
Appendix 3 - Deal type definitions
Appendix 4 - Example co-promotion contract document
Appendix 5 - Example co-marketing contract document
About CurrentPartnering

Recent report titles from CurrentPartnering - Order Form - Reports - Order form - Company Dealmaking Profiles - Order Form - Report Update Subscription - Order Form - CD-Rom

Figures in report
Figure 1: Definition of co-promotion and co-marketing
Figure 2: Trends in co-promotion deal announcements, 2000-2008
Figure 3: Co-promotion deals signed at what phase of development, 2000-2008
Figure 4: Trends in co-marketing deal announcements, 2000-2008
Figure 5: Co-marketing deals signed at what phase of development, 2000-2008
Figure 6: Situations where co-marketing can prove useful
Figure 7: Pure versus multi-component co-promotion deal announcements, 2000-2008
Figure 8: Stage of development at which pure and multi-component co-promotion deals are announced 2000-2008
Figure 9: Pure versus multi-component co-marketing deal announcements, 2000-2008
Figure 10: Stage of development at which pure and multi-component co-marketing deals are announced 2000-2008
Figure 11: Example deals where co-promotion options have been actively exercised, since 2000
Figure 12: Issues in implementing co-promotion agreements
Figure 13: Components of the co-promotion deal structure
Figure 14: Components of the co-marketing deal structure
Figure 15: Top 50 co-promotion deals by value since 2000
Figure 16: Top pure co-promotion deals by value since 2000
Figure 17: Top 50 co-promotion deals signed by bigpharma value since 2000
Figure 18: Most active co-promotion dealmakers 2006-7
Figure 19: Bigpharma - top 50 - co-promotion deals since 2003
Figure 20: Top co-marketing deals by value since 2000
Figure 21: Top pure co-marketing deals by value since 2000
Figure 22: Most active co-marketing dealmakers 2003-8
Figure 23: Bigpharma - top 50 - co-marketing deals since 2003
Figure 24: Online partnering resources
Figure 25: Deal type definitions
Figure 26: Co-promotion agreement between Bayer and Zymogenetics, June 2007
Figure 27: Co-marketing agreement between Schering-Plough and Ligand, January 2003

Purchase Information